Gelteq Ltd

Gelteq Limited provided a corporate update highlighting significant clinical and commercial milestones. The company completed planning for its first human clinical trial, anticipated to begin next quarter, and commenced a veterinary clinical trial for an antiparasitic drug candidate, targeting a 2026 FDA application. Gelteq also initiated a preclinical diabetes study, secured strategic debt financing of up to US$3.5 million, and manufactured a commercial product for a new East Asian customer. Additionally, the company established a Center of Excellence in China to accelerate product development and expand its global footprint.

Gelteq Limited announced the successful completion of its veterinary palatability trials conducted in collaboration with Kemin Industries. The trials demonstrated that Gelteq® technology effectively masked bitter flavor profiles and improved canine acceptance of products, including those deliberately formulated with bitter compounds. This validation is crucial for veterinary pharmaceutical applications, providing insights for future product development and strengthening Gelteq's position for strategic partnerships in the animal health sector. The company believes this significantly broadens the potential range of active pharmaceutical ingredients and formulations for its proprietary gel-based delivery platform.

Gelteq Limited announced the establishment of a new Center of Excellence in Guangdong Province, China. This strategic regional hub aims to integrate with and access China's fast-growing pharmaceutical and biotechnology ecosystem, enhancing Gelteq's global development platform. The center is expected to accelerate product development, expand capabilities, and increase capacity, aligning with the company's focus on international market expansion.

Gelteq Ltd has announced a Special Meeting of Shareholders to be held on June 19, 2026. The primary agenda item is Resolution 1, seeking shareholder approval for the issuance of shares upon the conversion of convertible notes. This issuance may exceed the 19.99% limit stipulated by Nasdaq Listing Rule 5635(d). The company intends to use the financing proceeds to fund strategic initiatives including commercialization, clinical trials, and operational scaling. The meeting will be conducted both in-person and virtually.

Gelteq Limited entered into a securities purchase agreement with an institutional investor for up to $3.5 million in debt financing. An initial tranche of $1.0 million (net of original issue discount) was funded through a $1.165 million convertible promissory note, accruing interest at 7% per annum with an 18-month maturity. A second tranche of $2.5 million (net) is subject to shareholder approval and the absence of trigger events, with similar terms to the initial note.

Gelteq Ltd. has commenced its first clinical trial for an antiparasitic drug candidate, marking its expansion into the veterinary pharmaceutical sector. This trial aims to support the company's planned FDA regulatory pathway for animal use, with a potential application targeted for later in 2026. The move reinforces the versatility of Gelteq® technology across human and animal health, positioning the company to participate in the growing global animal health market, estimated to exceed USD $78 billion in 2026. Gelteq is well-capitalized to pursue both pharmaceutical programs and its nutraceutical portfolio.

Gelteq Limited announced it has secured strategic debt financing of up to $3.5 million to accelerate its commercialization efforts, expand clinical trial activities, and capitalize on existing revenue opportunities. The financing will support scaling clinical trial programs for pharmaceutical products and ramping up commercialization of nutraceutical products. Gelteq will receive $1 million immediately, with an additional $2.5 million contingent on shareholder approval in June 2026, providing operational flexibility with no repayments for at least six months.